首页>投融资
Lupin
上市后再融资
Lupin Pharmaceuticals, a subsidiary of Lupin, is a transnational pharmaceutical company involved in the dedicated development of generic medications.In August 2020, Lupin Inc entered into an agreement with ForDoz Pharma for granting Lupin the exclusive rights to market and distribute two complex injectable assets in advanced stages of development in the US and its territories.In October 2017, the company acquired Symbiomix Therapeutics for a cash consideration of US $150 million including a US $50 million upfront and other time based payments with sales based contingent payments. The acquisition was funded from internal funds and the transaction was closed on October 11, 2017
基本信息
-
公司全称Lupin Pharmaceuticals Inc
-
类型原料药和仿制药生产商
-
产业领域原料药、药品研发/制造
-
公司人数500人以上
-
地址111 S Calvert St BALTIMORE MARYLAND 21202-6174; US;
-
联系电话+912266402222
-
邮箱corporateoffice@lupinworld.com
-
成立时间1968-01-01
投融资
-
2023-06-29上市后再融资2500万美元AbbVie
-
2018-12-27未透露9.77亿美元AbbVie
相关投融资企业
上市后再融资
Lupin Pharmaceuticals, a subsidiary of Lupin, is a transnational pharmaceutical company involved in the dedicated development of generic medications.In August 2020, Lupin Inc entered into an agreement with ForDoz Pharma for granting Lupin the exclusive rights to market and distribute two complex injectable assets in advanced stages of development in the US and its territories.In October 2017, the company acquired Symbiomix Therapeutics for a cash consideration of US $150 million including a US $50 million upfront and other time based payments with sales based contingent payments. The acquisition was funded from internal funds and the transaction was closed on October 11, 2017
未透露
Lupin Pharmaceuticals, a subsidiary of Lupin, is a transnational pharmaceutical company involved in the dedicated development of generic medications.In August 2020, Lupin Inc entered into an agreement with ForDoz Pharma for granting Lupin the exclusive rights to market and distribute two complex injectable assets in advanced stages of development in the US and its territories.In October 2017, the company acquired Symbiomix Therapeutics for a cash consideration of US $150 million including a US $50 million upfront and other time based payments with sales based contingent payments. The acquisition was funded from internal funds and the transaction was closed on October 11, 2017
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息